709 related articles for article (PubMed ID: 28369340)
1. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
[TBL] [Abstract][Full Text] [Related]
2. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
Filippatos G; Maggioni AP; Lam CSP; Pieske-Kraigher E; Butler J; Spertus J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Bamber L; Gheorghiade M; Pieske B
Eur J Heart Fail; 2017 Jun; 19(6):782-791. PubMed ID: 28586537
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M;
Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
[TBL] [Abstract][Full Text] [Related]
7. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
8. Rationale and Design of the VITALITY-HFpEF Trial.
Butler J; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; Wu Y; Carvalho F; Bamber L; Blaustein RO; Roessig L; Armstrong PW
Circ Heart Fail; 2019 May; 12(5):e005998. PubMed ID: 31096775
[TBL] [Abstract][Full Text] [Related]
9. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
[TBL] [Abstract][Full Text] [Related]
10. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Mittleman RS; Profy AT; Seferovic JP; Reasner D; Konstam MA
Am Heart J; 2020 Apr; 222():183-190. PubMed ID: 32105984
[TBL] [Abstract][Full Text] [Related]
13. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
Campbell N; Kalabalik-Hoganson J; Frey K
Ann Pharmacother; 2022 May; 56(5):600-608. PubMed ID: 34431706
[TBL] [Abstract][Full Text] [Related]
14. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Kang C; Lamb YN
Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
[TBL] [Abstract][Full Text] [Related]
16. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Coats AJS; Tolppanen H
Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
Trujillo ME; Arrington L; Patel Y; Passarell J; Wenning L; Blaustein RO; Armstrong PW; Meyer M; Becker C; Gheyas F
Clin Pharmacol Ther; 2022 Nov; 112(5):1061-1069. PubMed ID: 35841202
[TBL] [Abstract][Full Text] [Related]
18. [Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)].
Bauersachs J; Nitschmann S
Internist (Berl); 2020 Sep; 61(9):989-991. PubMed ID: 32591849
[No Abstract] [Full Text] [Related]
19. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
20. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
